Strategic partnerships Be The Match BioTherapies has a history of collaborating with biotech developers and pharma companies (Garuda Therapeutics, Chimeric Therapeutics, Orchard Therapeutics, NantKwest) to advance cell and gene therapies, presenting opportunities to pursue co-development, supply agreements, and off-the-shelf material collaborations with emerging CAR-T and gene therapy programs.

End-to-end solutions As the only provider offering customizable end-to-end cell therapy supply chain services, there is a clear sales angle to position Be The Match BioTherapies as a strategic supplier for sourcing, consented donor material, logistics, and regulatory-compliant materials for early- and late-stage programs seeking reliable CSCM (cell source material) and shipment infrastructure.

Global donor network With access to over 100,000 volunteer allogeneic donors and a track record of more than 6,500 time-sensitive shipments annually, there are opportunities to target programs requiring scalable donor sourcing, rapid material delivery, and global logistics support for multi-site trials.

Regulatory and data strength Long-term follow-up tracking via CIBMTR for FDA-approved CAR-T therapies and extensive cellular source material consent experience offer a compelling value prop for sponsors needing compliant data capture, post-market surveillance, and robust documentation across clinical and commercial programs.

Growth through biotech integration Active partnerships and a network-centric growth model indicate potential to expand collaborations with emerging cell therapy platforms, particularly those seeking off-the-shelf solutions, durable donor-derived materials, and alliance opportunities across Europe and other markets where Be The Match BioTherapies already has footprint.